Black Diamond Therapeutics, Inc. (BDTX)

NASDAQ: BDTX · IEX Real-Time Price · USD
5.04
+0.14 (2.86%)
Mar 28, 2024, 2:21 PM EDT - Market open

Company Description

Black Diamond Therapeutics, Inc., a clinical-stage precision oncology medicine company, focuses on the discovery and development of therapies for patients with genetically defined cancers.

The company's lead product candidate, BDTX-1535, a brain-penetrant, mutant selective, irreversible EGFR MasterKey inhibitor, designed to inhibit a family of oncogenic mutations, currently under Phase 1 clinical trial.

It also develops BDTX-4933, a brain penetrant RAF MasterKey inhibitor, designed to be a brain penetrant and highly selective and potent inhibitor of oncogenic BRAF Class I, II, III and active RAF dimers, expected to initiate Phase 1 clinical trial.

The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018.

Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Black Diamond Therapeutics, Inc.
Black Diamond Therapeutics logo
Country United States
Founded 2014
IPO Date Jan 30, 2020
Industry Biotechnology
Sector Healthcare
Employees 54
CEO Dr. Mark A. Velleca M.D., Ph.D.

Contact Details

Address:
One Main Street, 14th Floor
Cambridge, Massachusetts 02142
United States
Phone 617-417-5868
Website blackdiamondtherapeutics.com

Stock Details

Ticker Symbol BDTX
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $19.00
CIK Code 0001701541
CUSIP Number 09203E105
ISIN Number US09203E1055
SIC Code 2836

Key Executives

Name Position
Dr. Mark A. Velleca M.D., Ph.D. Chief Executive Officer, President and Chairman
Dr. David M. Epstein Ph.D. Co-Founder and Director
Dr. Fang Ni Pharm.D. Chief Financial Officer, Principal Financial Officer and Chief Business Officer
Brent Hatzis-Schoch Esq., J.D. Chief Operating Officer and General Counsel
Dr. Elizabeth Buck Ph.D. Co-Founder and Chief Scientific Officer
Erika Jones Vice President of Finance, Corporate Controller and Principal Accounting Officer
Elizabeth L. Montgomery Chief People Officer
Dr. Sergey Yurasov M.D., Ph.D. Chief Medical Officer
Melanie Morrison Chief Development Officer

Latest SEC Filings

Date Type Title
Mar 12, 2024 S-8 Securities to be offered to employees in employee benefit plans
Mar 12, 2024 10-K Annual Report
Mar 12, 2024 8-K Current Report
Mar 11, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 14, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Feb 13, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Jan 18, 2024 8-K Current Report
Jan 4, 2024 8-K Current Report
Dec 13, 2023 8-K Current Report
Nov 9, 2023 SC 13D/A [Amend] General statement of acquisition of beneficial ownership